目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T10140 | Dehydrogenase | ||
4-Diethylaminobenzaldehyde 是醛脱氢酶(ALDHs)的可逆抑制剂,对 ALDH1 的 Ki 为 4 nM,具有较强的抗雄激素作用 ,IC50为1.71 μM。 | |||
T19470 | Others Androgen Receptor | ||
Nandrolone propionate 是合成代谢类固醇,主要由雄激素和保氮剂组成,具有作用时间相对较长的特点。 | |||
T0488 | Reductase | ||
Finasteride (MK-906) 是 5α-还原酶的竞争性抑制剂,对 II 型 5α-还原酶的IC50为 4.2 nM,对 II 型 5α-还原酶的亲和力是 I 型酶的 100 倍。它可用于研究前列腺增生和雄激素性脱发。 | |||
T2207 | Androgen Receptor Endogenous Metabolite | ||
Adrenosterone (11-ketoandrostenedione) 是一种人内源性代谢物,由肾上腺皮质产生。Adrenosterone 是一种竞争性羟基类固醇脱氢酶 1 抑制剂。它是一种的类固醇激素,具有较弱的雄激素特性。它是一种膳食补充剂,能够减少脂肪并提高肌肉质量。它能够抑制人类癌细胞的转移进展。 | |||
T19213 | Others Androgen Receptor | ||
Boldenone Cypionate 是一种雄激素合成代谢类固醇,常被休闲健美运动员和普通健身房成员使用。 | |||
TC0026 | Others | ||
Testosterone benzoate 是一种合成的注射合成代谢雄激素类固醇 (AAS) 和一种雄激素酯。 | |||
T7957 | Others | ||
2-Isopropyl Thioxanthone 具有潜在的抗雌激素和抗雄激素特性。 | |||
T14843 | Androgen Receptor | ||
Bifluranol (BX341) 具有抗雄激素活性,在体内实验中显示出显著的抗前列腺活性,可用于治疗良性前列腺增生 (BPH)。 | |||
T11410L | Androgen Receptor | ||
GLPG0492 是一种非甾体选择性雄激素受体 (androgen receptor) 调节剂。GLPG0492 在肌肉骨骼疾病如肌萎缩和恶病质的研究方面具有潜在的潜力。 | |||
T1514 | Estrogen/progestogen Receptor Progesterone Receptor | ||
Norethindrone (Norethisterone) 是孕激素,能够用于子宫内膜异位症、由激素水平异常引起的子宫出血和继发性闭经的研究。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02672 | Prostatic Acid Phosphatase Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Prostatic acid phosphatase (PAP, or ACPP), also known as prostatic specific acid phosphatase (PSAP), is an enzyme produced by the prostate. As a non-specific phosphomonoesterase, Prostatic acid phosphatase is synthesized and secreted into seminal plasma under androgenic control. The enzyme is a dimer of molecular weight around 100 kDa. Prostatic acid phosphatase is a clinically important protein for its relevance as a biomarker of prostate carcinoma. Furthermore, it has a potential role in fertilization. The major action of PAP is to dephosphorylate macromolecules with the help of catalytic residues (His(12) and Asp(258)) that are located in the cleft between two domains. Cellular prostatic acid phosphatase (cPAcP), an authentic tyrosine phosphatase, is proposed to function as a negative growth regulator of prostate cancer (PCa) cells in part through its dephosphorylation of ErbB-2. cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Injection of the secretory isoform of PAP has potent antinociceptive effects in mouse models of chronic pain. This enzyme exhibits ecto-5'-nucleotidase activity, is widely distributed, and implicated in the formation of chronic pain. Additionally, PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.
|
|||||
TMPY-02155 | Prostatic Acid Phosphatase Protein, Human, Recombinant (His) | Human | HEK293 | ||
Prostatic acid phosphatase (PAP, or ACPP), also known as prostatic specific acid phosphatase (PSAP), is an enzyme produced by the prostate. As a non-specific phosphomonoesterase, Prostatic acid phosphatase is synthesized and secreted into seminal plasma under androgenic control. The enzyme is a dimer of molecular weight around 100 kDa. Prostatic acid phosphatase is a clinically important protein for its relevance as a biomarker of prostate carcinoma. Furthermore, it has a potential role in fertilization. The major action of PAP is to dephosphorylate macromolecules with the help of catalytic residues (His(12) and Asp(258)) that are located in the cleft between two domains. Cellular prostatic acid phosphatase (cPAcP), an authentic tyrosine phosphatase, is proposed to function as a negative growth regulator of prostate cancer (PCa) cells in part through its dephosphorylation of ErbB-2. cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Injection of the secretory isoform of PAP has potent antinociceptive effects in mouse models of chronic pain. This enzyme exhibits ecto-5'-nucleotidase activity, is widely distributed, and implicated in the formation of chronic pain. Additionally, PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.
|